Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Compare within a sector
MetricNVSNovartis AGAZNAstraZeneca PLCMRKMerck & Co.
Snapshot
Price$154.07$168.69$126.06
Market cap$261.56B$284.73B$319.99B
Valuation
P/E21.4x25.9x34.7x
Forward P/E19.5x19.4x49.6x
Growth
Revenue growth5.8%9.9%2.9%
EPS growth9.3%33.7%-48.3%
Profitability
Net margin24.1%17.2%13.6%
ROE31.7%22.3%17.9%
Balance sheet & cash
Debt / equity0.77x0.61x0.94x
Free cash flow yield4.2%3.1%2.9%
Dividend yield2.9%1.7%3.0%
Verdict
Investment ratingFavorable· 67Favorable· 62Weak· 40

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearNVStoday $154AZNtoday $169MRKtoday $126
2027$126.26 – $185.19+20% CAGR$169.17 – $248.11+47% CAGR$96.44 – $141.44+12% CAGR
2028$137.97 – $202.35+15% CAGR$226.19 – $331.75+40% CAGR$98.36 – $144.27+7% CAGR
2029$150.76 – $221.11+13% CAGR$302.44 – $443.58+38% CAGR$100.33 – $147.15+5% CAGR
2030$164.73 – $241.61+12% CAGR$404.40 – $593.11+37% CAGR$102.34 – $150.10+4% CAGR
2031$180.00 – $264.01+11% CAGR$540.72 – $793.05+36% CAGR$104.39 – $153.10+4% CAGR
5-yr CAGR3.2% – 11.4%26.2% – 36.3%-3.7% – 4.0%